Undisclosed Lead Program (e.g., CTT-001)

About Ceres Brain Therapeutics

Ceres Brain Therapeutics, founded in 2019, is a pioneering biotech focused on treating cerebral diseases by targeting brain energy metabolism. Its primary mission is to develop the first effective therapy for Creatine Transporter Deficiency (CTD), a devastating and currently untreatable pediatric neurological disorder. The company is leveraging a deep understanding of the creatine transport system to advance its lead program through pre-clinical development. Its strategic direction involves establishing proof-of-concept in CTD before potentially expanding its platform to other neurological conditions characterized by energy deficits.

Therapeutic Areas